Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Short Interest Update

Invesco Pharmaceuticals ETF (NYSEARCA:PJP) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totaling 16,116 shares, a growth of 2,312.6% from the May 31st total of 668 shares. Based on an average trading volume of 18,819 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.5% of the shares of the stock are sold short.

Invesco Pharmaceuticals ETF Trading Up 2.6%

NYSEARCA:PJP traded up $2.99 during trading hours on Friday, reaching $118.67. 26,231 shares of the company were exchanged, compared to its average volume of 32,992. The firm has a market cap of $388.05 million, a PE ratio of 15.59 and a beta of 0.46. Invesco Pharmaceuticals ETF has a twelve month low of $79.47 and a twelve month high of $118.88. The stock’s 50-day moving average is $108.77 and its 200-day moving average is $106.71.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Fifth Third Bancorp acquired a new stake in Invesco Pharmaceuticals ETF in the 1st quarter worth about $36,000. Global Assets Advisory LLC purchased a new stake in shares of Invesco Pharmaceuticals ETF during the first quarter worth $42,000. IFP Advisors Inc lifted its stake in shares of Invesco Pharmaceuticals ETF by 31.3% in the fourth quarter. IFP Advisors Inc now owns 440 shares of the company’s stock worth $46,000 after buying an additional 105 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in Invesco Pharmaceuticals ETF in the 4th quarter valued at about $64,000. Finally, Rockefeller Capital Management L.P. raised its holdings in Invesco Pharmaceuticals ETF by 20.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,230 shares of the company’s stock valued at $129,000 after acquiring an additional 209 shares during the last quarter.

About Invesco Pharmaceuticals ETF

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.